Clinical Trials in Baltimore

Showing 1781-1800 of 11,213 trials

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

NCT04033926

This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM). Patients were evaluated for eligibility during the Screening Period. Eligible patients were stratified by diagnosis of DM or PM and randomized 1:1 to Arm A or Arm B of the study. During the 32-week treatment period, patients received study drug subcutaneously (SC) once weekly with 2 treatment periods of 16 weeks each. This study was conducted on an outpatient basis.

PolymyositisDermatomyositis

Kezar Life Sciences, Inc.25 participantsStarted Jan 2020

Beverly Hills, California, United States • Orange, California, United States • Miami, Florida, United States +11 more locations

Active Not RecruitingPhase 3< 1 mile

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

Advanced or Metastatic Non-Small Cell Lung Cancer

AstraZeneca594 participantsStarted Sep 2022

Mobile, Alabama, United States • Chandler, Arizona, United States • Los Alamitos, California, United States +190 more locations

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Find Trials by Condition in Baltimore

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration

MARGetuximab Or Trastuzumab (MARGOT)

The Synergy Disc To Anterior Cervical Discectomy and Fusion

Study of AVZO-021 in Patients With Advanced Solid Tumors

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Natural History Study Protocol in PMM2-CDG (CDG-Ia)

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

Pharmacogenomics for Better Treatment of Fungal Infections in Cancer